LifeMD, Inc. — Q1 2024 Form 10-Q Summary
Business context and reporting period. The unaudited filing covers the three months ended March 31, 2024, compared with Q1 2023. LifeMD operates direct-to-patient telehealth services and owns approximately 73.3% of WorkSimpli, a subscription software business. Telehealth includes primary care, weight management and specialty offerings; the company reported more than 235,000 active patient subscribers and over 42,000 weight-management subscribers at quarter-end.
Financial performance and position
- Revenue: $44.1 million, up 33% year over year. Telehealth revenue was $30.8 million, up 53%; WorkSimpli revenue was $13.3 million, up 3%. Revenue included approximately $2.0 million recognized from the Medifast collaboration.
- Profitability and margins: Gross profit was $39.5 million, up 37%; gross margin was 89.6%, versus 87.3%. Operating loss widened to $6.2 million from $2.9 million. Net loss attributable to common stockholders was $7.5 million, or $0.19 per share, versus $4.8 million, or $0.15 per share.
- Expenses: Operating expenses rose 44% to $45.7 million. Selling and marketing increased $7.5 million, primarily to support LifeMD primary care growth; general and administrative expenses increased about $4.7 million, including higher compensation and legal and professional fees.
- Cash flow: Operating activities provided $5.2 million, versus $2.6 million used in Q1 2023. The 2024 inflow included a $4.4 million increase in deferred revenue and higher accounts payable and accrued expenses; investing activities used $2.2 million, chiefly for software development. Financing activities used $1.0 million. Cash rose to $35.1 million from $33.1 million at year-end.
- Liquidity: Current assets were $44.4 million and current liabilities $44.7 million, leaving negative working capital of $0.3 million, compared with positive working capital of $7.8 million at December 31, 2023. Current liabilities increased, including a $4.4 million increase in deferred revenue and $4.0 million of current long-term debt.
- Debt and capital: Avenue Facility borrowings were $19.0 million outstanding, with a 13.25% interest rate at March 31 and maturity on October 1, 2026. The company reported compliance with its covenants, which include minimum unrestricted cash of $5 million and an adjusted trailing six-month cash-flow requirement. Series A preferred dividends were $776,563 for the quarter.
- Equity: Common shares issued increased from 38.36 million at December 31 to 40.73 million at March 31. Stock-based compensation was $2.5 million. The company reported $53.3 million available under its ATM agreement and $32.0 million under its 2021 shelf registration statement.
Changes versus Q1 2023
- Telehealth growth, including LifeMD primary care and Medifast collaboration revenue, drove most of the consolidated revenue increase; WorkSimpli grew more modestly.
- Gross margin improved, including telehealth segment margin of 86.4% versus 80.6%; WorkSimpli margin was 97.0% versus 97.7%.
- Higher operating expenses outpaced gross-profit growth, increasing the operating loss. Interest expense also rose by approximately $213,000; Q1 2023 additionally included a $325,000 debt-extinguishment loss.
- Operating cash flow improved from an outflow to an inflow, but depended in part on deferred revenue and payables growth. Cash used in investing rose to $2.2 million; Q1 2023 financing had included substantial debt proceeds.
Outlook, risks and unusual items
- Management expects further losses through 2024 but anticipates improving cash burn and positive operating cash flow over the next 12 months. It states that available cash and financing sources support its expectation of sufficient liquidity for that period; this depends on revenue growth, operational efficiencies and, if needed, expense reductions. No specific revenue or earnings guidance was provided.
- The Medifast collaboration provides for $10 million of support payments: $7.5 million had been received by March 31, with the remaining $2.5 million due by June 30, 2024 or earlier upon specified milestones. Separately, a private placement with Medifast’s subsidiary generated approximately $10 million for 1,224,425 shares.
- The company reported an accumulated deficit of approximately $221.8 million and identified continued operations as dependent on increased sales or additional common-stock issuance. The Avenue Facility also carries covenant and repayment obligations.
- Management concluded disclosure controls were ineffective because of material weaknesses in IT access, change-management and vendor controls, as well as business-process documentation and review controls. Remediation is underway; management said the weaknesses had not caused a financial-statement misstatement.
- The IRS asserted an approximately $1.9 million tax deficiency for 2019. LifeMD disputes the assessment in Tax Court and says it intends to defend the case.
- Management cited risks including competition, customer acceptance, customer and supplier relationships, cybersecurity, technology, regulation, supply-chain issues, financing needs and the ability to scale profitably. The filing says there were no material changes to the risk factors in the 2023 Form 10-K.
Important facts for investors to verify
- Whether growth in telehealth and weight management can translate into improved operating results given the 44% rise in operating expenses and widening operating loss.
- How much of operating cash flow is recurring versus attributable to deferred revenue, payables and accrued-expense movements.
- Liquidity and covenant headroom, upcoming Avenue principal payments, and the company’s ability to sustain its stated 12-month cash outlook. The filing reports $35.1 million cash at March 31, while also citing approximately $29.3 million “as of the filing date”; confirm the respective dates and cash position.
- Progress and testing of remediation for the disclosed material weaknesses, and the status and potential financial outcome of the IRS dispute.
- Further share issuance, dilution and use of ATM or shelf capacity, alongside the timing and conditions for the remaining Medifast collaboration payment.